A study collecting blood and tissue samples to look at the genes of early lung cancer detected through screening (ASCENT)

Cancer type:

Lung cancer
Non small cell lung cancer

Status:

Open

Phase:

Other

This study is collecting samples from people diagnosed with lung cancer. The samples could be:

  • tissue samples only or
  • both blood and tissue samples

It is also for people suspected of having lung cancer. It is open to people who took part in the:

More about this trial

The SUMMIT study and the NHS Targeted Lung Heath Check (TLHC) programme are looking at using low dose CT scans Open a glossary item to diagnose lung cancer. As part of the SUMMIT study if your CT scan shows you have lung cancer or might have lung cancer you have surgery to remove it

The SUMMIT study is developing a test to find cancer in the blood. 

In the ASCENT study the team take:

  • tissue samples only
  • or both blood and tissue samples

They take the tissue sample from the cancer tissue removed during surgery. 

They use these samples to look at the genes Open a glossary item of the cancer cells and biomarkers Open a glossary item.

They also look at the results of any scans or tests you have from the time of screening to surgery. The team want to see if they can identify patterns that might suggest lung cancer. Their hope is that by doing this in the future doctors might be able to better understand and diagnose lung cancer. 

Please note you won’t get any direct benefit from taking part. 

Who can enter

The following bullet points list the entry conditions for this study. Talk to your doctor or the study team if you are unsure about any of these. They will be able to advise you. 

Who can take part

You may be able to join this study if you are taking part in the SUMMIT study or the TLHC programme and all of the following apply. You:

  • have lung cancer or might have lung cancer
  • are to have or have had  surgery to remove the cancer

Who can’t take part

You cannot join this study if any of these apply. You:

  • are to have chemotherapy or radiotherapy to shrink the cancer before surgery (neo adjuvant treatment)
  • have an active infection of HIV, hepatitis B, hepatitis C or syphilis

Trial design

The study team need about 336 people who took part in the SUMMIT study or the TLHC programme to join.

The team want people who are to have surgery or have already had surgery to join. 

People who are to have surgery

You give 4 samples of blood. You give these on the day you have surgery.

The team take a small sample of the tissue (biopsy Open a glossary item) removed during surgery.

People who have already had surgery 

The team ask for a small sample of the tissue removed from when you had surgery. 

They use these samples to look at the DNA Open a glossary item and for biomarkers Open a glossary item. They will also look at the results of any scans you have and compare them. This is to see if they can find any patterns that might suggest better ways to diagnose lung cancer in the future.

Hospital visits

There are no extra hospital visits in this study.

Side effects

There are no side effects apart from some possible slight bleeding or bruising from the blood samples.

Location

London

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Sam Janes

Supported by

Cancer Research UK
University College London (UCL)
National Institute for Health Research (NIHR)

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

17224

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Wendy took part in a new trial studying the possible side effect of hearing loss

A picture of Wendy

"I was delighted to take part in a clinical trial as it has the potential to really help others in the future.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think